Aquestive Therapeutics (AQST) Net Margin (2017 - 2026)

Aquestive Therapeutics has reported Net Margin for 10 years, with the latest figure at 165.45% in Q2 2026.

• On a quarterly basis, Net Margin fell 3001.0% year-over-year to 165.45% in Q2 2026; TTM through Jun 2026 was 144.63%, a 275.0% increase from a year earlier, with the FY2025 full-year figure at 188.09%, down 11141.0% from the prior year.
• Net Margin was 165.45% for Q2 2026 at Aquestive Therapeutics, down from 55.77% in the prior quarter.
• The five-year high for Net Margin was 72.46% in Q1 2023, with the low at 262.96% in Q1 2025.
• Average Net Margin over 5 years is 102.1%, with a median of 108.55% recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Net Margin plunged 17889 bps in 2024, then jumped 20719 bps in 2026.
• Over 5 years, Net Margin stood at 115.63% in 2022, then surged by 47 bps to 61.42% in 2023, then plunged by 134 bps to 143.72% in 2024, then plunged by 70 bps to 244.79% in 2025, then jumped by 32 bps to 165.45% in 2026.
• The last three Net Margin figures came in at 165.45% (Q2 2026), 55.77% (Q1 2026), and 244.79% (Q4 2025), per Business Quant data.